Dated: August 1, 2022. **Andrew McGilvray**, *Executive Secretary*. [FR Doc. 2022–16810 Filed 8–4–22; 8:45 am] **BILLING CODE 3510–DS–P**

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-29-2022]

Foreign-Trade Zone (FTZ) 57— Mecklenburg County, North Carolina; Notification of Proposed Production Activity, Exela Pharma Sciences, LLC, (Pharmaceutical Products), Lenoir, North Carolina

The Charlotte Regional Business Alliance, grantee of FTZ 57, submitted a notification of proposed production activity to the FTZ Board (the Board) on behalf of Exela Pharma Sciences, LLC, located in Lenoir, North Carolina within Subzone 57D. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 28, 2022.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status components and specific finished product described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via *www.trade.gov/ ftz.*

The proposed finished product is a Covid–19 vaccine (duty-free).

The proposed foreign-status components are type 1 borosilicate glass vials (2 milliliters) and rubber stoppers for vials (duty rate ranges from duty-free to 2.7%). The request indicates the components are subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: *ftz@trade.gov*. The closing period for their receipt is September 14, 2022.

 copy of the notification will be available for public inspection in the "Online FTZ Information System" section of the Board's website.

For further information, contact Christopher Wedderburn at *Chris.Wedderburn@trade.gov.* Dated: August 1, 2022. Andrew McGilvray, Executive Secretary. [FR Doc. 2022–16812 Filed 8–4–22; 8:45 am] BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[S-91-2022]

Approval of Expansion of Subzone 168G; Sager Electronics, Lewisville, Texas

On June 8, 2022, the Executive Secretary of the Foreign-Trade Zones (FTZ) Board docketed an application submitted by Metroplex International Trade Development Corporation, grantee of FTZ 168, requesting expanded subzone status subject to the existing activation limit of FTZ 168, on behalf of Sager Electronics, in Lewisville, Texas.

The application was processed in accordance with the FTZ Act and Regulations, including notice in the **Federal Register** inviting public comment (87 FR 35967, June 14, 2022). The FTZ staff examiner reviewed the application and determined that it meets the criteria for approval.

Pursuant to the authority delegated to the FTZ Board Executive Secretary (15 CFR 400.36(f)), the application to expand Subzone 168G was approved on August 2, 2022, subject to the FTZ Act and the Board's regulations, including Section 400.13, and further subject to FTZ 168's 1,955.59-acre activation limit.

Dated: August 2, 2022.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2022–16842 Filed 8–4–22; 8:45 am] BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-32-2022]

Foreign-Trade Zone (FTZ) 27—Boston, Massachusetts; Notification of Proposed Production Activity, Wyeth Pharmaceuticals, LLC, (COVID–19 Vaccine), Andover, Massachusetts

Wyeth Pharmaceuticals, LLC (Wyeth) submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Andover, Massachusetts within Subzone 27R. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on July 27, 2022.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status materials/ components and specific finished product described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/ ftz. The proposed finished product and materials/components would be added to the production authority that the Board previously approved for the operation, as reflected on the Board's website.

The proposed finished product is COVID–19 vaccine (duty-free).

The proposed foreign-status materials and components include mRNA drug substance, PF-07311356 ALC-0315 Lipid, 2-[(Polyethylene Glycol)-2000]-N,N-Ditetradecylacetamide (PEG Lipid ALC-0159), and 1,2-Distearoyl-snglycero-3-phosphocoline (DSPC) (duty rate ranges from 3.7% to 6.5%). The request indicates that certain materials/ components are subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: *ftz@trade.gov*. The closing period for their receipt is September 14, 2022.

A copy of the notification will be available for public inspection in the "Online FTZ Information System" section of the Board's website.

For further information, contact Diane Finver at *Diane.Finver@trade.gov.*

Dated: August 1, 2022.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2022–16811 Filed 8–4–22; 8:45 am] BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-31-2022]

Foreign-Trade Zone (FTZ) 222— Birmingham, Alabama; Notification of Proposed Production Activity, Hyundai Motor Manufacturing Alabama, LLC (Passenger Automobiles, Trucks, and Cargo Trucks), Montgomery, Alabama

Hyundai Motor Manufacturing Alabama, LLC (HMMA) submitted a